Table 4 Odds ratios (ORs) and 95% confidence interval (CIs) of Ang2 genotypic frequencies and clinical subtypes in patients with malignant breast neoplasms.

From: The impact of Angiopoietin-2 genetic polymorphisms on susceptibility for malignant breast neoplasms

Variable

Luminal A (n = 128)

Luminal B (n = 206)

HER2 overexpression (n = 68)

TNBC (n = 62)

Clinical stage

OR (95% CI)

Clinical stage

OR (95% CI)

Clinical stage

OR (95% CI)

Clinical stage

OR (95% CI)

Stage I/II

Stage III/IV

Stage I/II

Stage III/IV

Stage I/II

Stage III/IV

Stage I/II

Stage III/IV

rs1823375

N = 109 (%)

N = 19 (%)

N = 155(%)

N = 51(%)

N = 49 (%)

N = 19 (%)

N = 52 (%)

N = 10 (%)

CC

51 (46.8)

8 (42.1)

1.00 (reference)

70 (45.2)

24 (47.1)

1.00 (reference)

18 (36.7)

11 (57.9)

1.00 (reference)

24 (46.2)

4 (40.0)

1.00 (reference)

CG

48 (44.0)

10 (52.6)

1.328 (0.484–3.646)

69 (44.5)

25 (49.0)

1.057 (0.551–2.027)

23 (46.9)

8 (42.1)

0.569 (0.189–1.710)

24 (46.2)

6 (60.0)

1.500 (0.375–5.998)

GG

10 (9.2)

1 (5.3)

0.638 (0.072–5.677)

16 (10.3)

2 (3.9)

0.365 (0.078–1.703)

8 (16.3)

0 (0)

–

4 (7.7)

0 (0)

–

CG+GG

58 (53.2)

11 (57.9)

1.209 (0.451–3.239)

85 (54.8)

27 (52.9)

0.926 (0.491–1.747)

31 (63.3)

8 (42.1)

0.422 (0.143–1.244)

28 (53.8)

6 (60.0)

1.286 (0.324–5.098)

Variable

Luminal A (n = 128)

Luminal B (n = 206)

HER2 overexpression (n = 68)

TNBC (n = 62)

Tumor size

OR (95% CI)

Tumor size

OR (95% CI)

Tumor size

OR (95% CI)

Tumor size

OR (95% CI)

< T2

≧T2

< T2

≧T2

< T2

≧T2

< T2

≧T2

rs1823375

N = 85(%)

N = 43(%)

N = 83(%)

N = 123(%)

N = 22(%)

N = 46(%)

N = 25(%)

N = 37(%)

CC

43 (50.6)

16 (37.2)

1.00 (reference)

37 (44.6)

57 (46.3)

1.00 (reference)

8 (36.4)

21 (45.7)

1.00 (reference)

12 (48.0)

16 (43.2)

1.00 (reference)

CG

35 (41.2)

23 (53.5)

1.766 (0.811–3.847)

37 (44.6)

57 (46.3)

1.000 (0.557–1.795)

12 (54.5)

19 (41.3)

1.603 (0.203–1.792)

11 (44.0)

19 (51.4)

1.295 (0.451–3.718)

GG

7 (8.2)

4 (9.3)

1.536 (0.396–5.959)

9 (10.8)

9 (7.3)

0.649 (0.236–1.786)

2 (9.1)

6 (13.0)

1.143 (0.190–6.883)

2 (8.0)

2 (5.4)

0.750 (0.092–6.112)

CG+GG

42 (49.4)

27 (62.8)

1.728 (0.816–3.659)

46 (55.4)

66 (53.7)

0.931 (0.532–1.630)

14 (63.6)

25 (54.3)

0.680 (0.239–1.933)

13 (52.0)

21 (56.8)

1.212 (0.437–3.357)

Variable

Luminal A (n = 128)

Luminal B (n = 206)

HER2 overexpression (n = 68)

TNBC (n = 62)

Lymph node status

OR (95% CI)

Lymph node status

OR (95% CI)

Lymph node status

OR (95% CI)

Lymph node status

OR (95% CI)

N0

N1–N3

N0

N1–N3

N0

N1–N3

N0

N1–N3

rs1823375

N = 85(%)

N = 43(%)

N = 103(%)

N = 103(%)

N = 32(%)

N = 36(%)

N = 35(%)

N = 27(%)

CC

39 (45.9)

20 (46.5)

1.00 (reference)

48 (46.6)

46 (44.7)

1.00 (reference)

9 (28.1)

20 (55.6)

1.00 (reference)

16 (45.7)

12 (44.4)

1.00 (reference)

CG

39 (45.9)

19 (44.2)

0.950 (0.440–2.050)

44 (42.7)

50 (48.5)

1.186 (0.669–2.102)

18 (56.3)

13 (36.1)

0.325 (0.112–0.940)*

17 (48.6)

13 (48.1)

1.020 (0.360–2.885)

GG

3 (8.2)

4 (9.3)

1.114 (0.291–4.262)

11 (10.7)

7 (6.8)

0.664 (0.237–1.861)

5 (15.6)

3 (8.3)

0.270 (0.053–1.383)

2 (5.7)

2 (7.4)

1.333 (0.164–10.867)

CG+GG

46 (54.1)

23 (53.5)

0.975 (0.467–2.035)

55 (53.4)

57 (55.3)

1.081 (0.625–1.871)

23 (71.9)

16 (44.4)

0.313 (0.114–0.862)*

19 (54.3)

15 (55.6)

1.053 (0.384–2.888)

Variable

Luminal A (n = 128)

Luminal B (n = 206)

HER2 overexpression (n = 68)

TNBC (n = 62)

Distant metastasis

OR (95% CI)

Distant metastasis

OR (95% CI)

Distant metastasis

OR (95% CI)

Distant metastasis

OR (95% CI)

M0

M1

M0

M1

M0

M1

M0

M1

rs1823375

N = 127(%)

N = 1(%)

N = 201(%)

N = 5(%)

N = 65(%)

N = 3(%)

N = 59(%)

N = 3(%)

CC

59 (46.5)

0 (0)

1.00 (reference)

90 (44.8)

4 (80.0)

1.00 (reference)

28 (43.1)

1 (33.3)

1.00 (reference)

27 (45.8)

1 (33.3)

1.00 (reference)

CG

57 (44.9)

1 (100.0)

–

93 (46.3)

1 (20.0)

0.242 (0.027–2.206)

29 (44.6)

2 (66.7)

1.931 (0.166–22.512)

28 (47.5)

2 (66.7)

1.929 (0.165–22.528)

GG

11 (8.7)

0 (0)

–

18 (9.0)

0 (0)

–

8 (12.3)

0 (0)

–

4 (6.8)

0 (0)

–

CG+GG

68 (53.5)

1 (100.0)

–

111 (55.2)

1 (20.0)

0.203 (0.022–1.846)

37 (56.9)

2 (66.7)

1.514 (0.131–17.542)

32 (54.2)

2 (66.7)

1.688 (0.145–19.643)

Variable

Luminal A (n = 128)

Luminal B (n = 206)

HER2 overexpression (n = 68)

TNBC (n = 62)

Pathological grade

OR (95% CI)

Pathological grade

OR (95% CI)

Pathological grade

OR (95% CI)

Pathological grade

OR (95% CI)

I

II + III

I

II + III

I

II + III

I

II + III

rs1823375

N = 35(%)

N = 93(%)

N = 7(%)

N = 199(%)

N = 2(%)

N = 66(%)

N = 1(%)

N = 61(%)

CC

18 (51.4)

41 (44.1)

1.00 (reference)

3 (42.9)

91 (45.7)

1.00 (reference)

1 (50.0)

28 (42.4)

1.00 (reference)

0 (0)

28 (45.9)

1.00 (reference)

CG

15 (42.9)

43 (46.2)

1.259 (0.561–2.823)

3 (42.9)

91 (45.7)

1.000 (0.197–5.086)

1 (50.0)

30 (45.5)

1.071 (0.064–17.962)

0 (0)

30 (49.2)

–

GG

2 (5.7)

9 (9.7)

1.976 (0.387–10.076)

1 (14.3)

17 (8.5)

0.560 (0.055–5.712)

0 (0)

8 (12.1)

–

1 (100.0)

3 (4.9)

–

CG+GG

17 (48.6)

52 (55.9)

1.343 (0.616–2.927)

4 (57.1)

108 (54.3)

0.890 (0.194–4.081)

1 (50.0)

38 (57.6)

1.357 (0.081–22.643)

1 (100.0)

33 (54.1)

–

  1. The ORs and their associated 95% CIs were estimated by logistic regression models. *p < 0.05 was considered to be statistically significant. HER2, human epidermal growth factor receptor 2; TNBC, triple-negative breast cancer. Pathological grade: I, well differentiated; II, moderately differentiated; III, poorly differentiated.
  2. Significant values are in bold.
Back to article page